LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

MRK

117.82

-0.52%↓

Search

AbbVie Inc

Cerrado

Sector Salud

193.18 0.34

Resumen

Variación precio

24h

Actual

Mínimo

192.93

Máximo

194.14

Métricas clave

By Trading Economics

Ingresos

1M

1.4B

Ventas

2.2B

14B

P/B

Media del Sector

51.05

103.001

BPA

2.65

Margen de beneficio

9.474

Empleados

50,000

EBITDA

514M

5B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+2.24 upside

Dividendos

By Dow Jones

Próximas Ganancias

25 oct 2024

Fecha Próximo Dividendo

15 nov 2024

Próxima Fecha de Ex Dividendo

15 oct 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

348B

Apertura anterior

192.84

Cierre anterior

193.18

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

39 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

AbbVie Inc Gráfico

Noticias Relacionadas

25 jul 2024, 12:18 UTC

Ganancias

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27 jun 2024, 13:58 UTC

Adquisiciones, fusiones, absorciones

AbbVie Buys Celsius Therapeutics for $250 Million

26 abr 2024, 20:53 UTC

Principales Movimientos del Mercado

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 abr 2024, 12:25 UTC

Ganancias

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

12 ago 2024, 14:30 UTC

Adquisiciones, fusiones, absorciones

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 ago 2024, 09:30 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 ago 2024, 12:23 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Cerevel Therapeutics >ABBV CERE

29 jul 2024, 10:30 UTC

Principales Noticias

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25 jul 2024, 13:01 UTC

Ganancias

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25 jul 2024, 12:46 UTC

Principales Noticias
Ganancias

AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.' -- Barrons.com

25 jul 2024, 11:36 UTC

Ganancias

AbbVie Sees FY Adj EPS $10.71-Adj EPS $10.91 >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q EPS 77c >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Rev $14.46B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global Skyrizi Rev $2.73B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q U.S. HUMIRA Rev $2.36B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q International HUMIRA Rev $454M >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Adj EPS $2.65 >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Net $1.37B >ABBV

25 jul 2024, 11:36 UTC

Ganancias

AbbVie 2Q Global IMBRUVICA Rev $833M >ABBV

25 jul 2024, 08:40 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

27 jun 2024, 13:28 UTC

Adquisiciones, fusiones, absorciones

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27 jun 2024, 13:28 UTC

Adquisiciones, fusiones, absorciones

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27 jun 2024, 13:26 UTC

Adquisiciones, fusiones, absorciones

AbbVie Acquires Celsius Therapeutics >ABBV

23 may 2024, 20:05 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7 may 2024, 20:30 UTC

Principales Noticias

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26 abr 2024, 13:03 UTC

Ganancias

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26 abr 2024, 12:04 UTC

Ganancias

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26 abr 2024, 11:41 UTC

Ganancias

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

2.24% repunte

Estimación a 12 meses

Media 197.73 USD  2.24%

Máximo 218 USD

Mínimo 170 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

10

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

192.16 / 196.2271Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

39 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.